Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00404274 · ClinicalTrials.gov registry record · Phase 1
A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 97
- Enrollment target
NCT00404274 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 97 participants.
The verdict
NCT00404274, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 97 participants
- Enrollment target
Study Summary
GW679769 may affect liver enzymes that metabolize warfarin. This study is designed to test the extent of the GW679769 affect on Warfarin levels in humans.
Interventions
- DRUG Casopitant (GW679769) oral tablets
- DRUG Warfarin oral tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2006-11-01 |
| Est. Completion | 2007-03-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00404274
The ClinicalTrials.gov registry entry for NCT00404274 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Casopitant (GW679769) oral tablets is the first listed.
NCT00404274 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00404274 about?
NCT00404274 is a clinical study titled "A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers". GW679769 may affect liver enzymes that metabolize warfarin. This study is designed to test the extent of the GW679769 affect on Warfarin levels in humans.
What is the current status of trial NCT00404274?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 97 participants. The study started on 2006-11-01. Estimated completion is 2007-03-18.
What interventions are being tested in trial NCT00404274?
The interventions under investigation include: Casopitant (GW679769) oral tablets (DRUG), Warfarin oral tablets (DRUG).
Who is sponsoring clinical trial NCT00404274?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.